Galectins are thought to be prognosticators for survival in renal cell cancer. However, the biological activity of galectin-3 (Gal-3) in renal carcinoma cells is still debated. In this study, immunohistochemical staining confirmed a high expression of Gal-3 in tumor tissue from renal cell carcinoma. Critically, Gal-3 expression was related to tumor cell differentiation. Consistent with Gal-3 expression in renal cell cancer, strong expression of Gal-3 was also observed in several renal tumor cell lines but not in normal renal cells. A Gal-3 high-expression cell line Caki-1 was chosen to study the biological activity of Gal-3. Using short hairpin RNA method, Gal-3 expression in Caki-1 cells was knocked down. We evidenced that Gal-3 knockdown inhibited cell proliferation and invasion, induced Caspase-3-dependent apoptosis and arrested cell cycle at G1 phase. Mechanically, Cyclin D1 expression decreased, but p27 increased after Gal-3 knockdown. Taken together, these results suggest that Gal-3 is related to the development of renal cell cancer and could serve as a target to therapy renal cell cancer.
TanHJFilsonCPLitwinMS. Contemporary, age-based trends in the incidence and management of patients with early-stage kidney cancer. Urol Oncol2015; 33: 21.e19–e26.
2.
van der VeldtAAMeijerinkMRvan den EertweghAJBovenE. Targeted therapies in renal cell cancer: recent developments in imaging. Targeted Oncol2010; 5: 95–112.
3.
ThijssenVLHeusschenRCaersJGriffioenAW. Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochim Biophys Acta2015; 1855: 235–247.
4.
FrenchBWangLKyBBrandimartoJBasurayAFangJCSweitzerNKCappolaTP. Prognostic value of galectin-3 for adverse outcomes in chronic heart failure. J Card Fail 2015.doi: 10.1016/j.cardfail.2015.10.022.
5.
Martinez-MartinezECalvierLFernandez-CelisARousseauEJurado-LopezRRossoniLVJaisserFZannadFRossignolPCachofeiroVLópez-AndrésN. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension2015; 66: 767–775.
6.
NewlaczylAUYuLG. Galectin-3—a jack-of-all-trades in cancer. Cancer Lett2011; 313: 123–128.
7.
von KlotCAKramerMWPetersIHennenlotterJAbbasMSchererRHerrmannTRStenzlAKuczykMASerthJMerseburgerAS. Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma. BMC Clin Pathol2014; 14: 15–15.
8.
KanekoNGotohAOkamuraNMatsuoETeraoSWatanabeMYamadaYHamamiGNakamuraTIkekitaMOkumuraKNishimuraO. Potential tumor markers of renal cell carcinoma: alpha-enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection. Int J Urol2013; 20: 530–535.
9.
StraubeTElliAFGrebCHegeleAElsässerHPDelacourDJacobR. Changes in the expression and subcellular distribution of galectin-3 in clear cell renal cell carcinoma. J Exp Clin Cancer Res2011; 30: 89–89.
10.
FrançoisCvan VelthovenRDe LathouwerOMorenoCPeltierAKaltnerHSalmonIGabiusHJDanguyADecaesteckerCKissR. Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas. Am J Clin Pathol1999; 112: 194–203.
11.
MerseburgerASKramerMWHennenlotterJSerthJKruckSGraciaAStenzlAKuczykMA. Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J Urol2008; 26: 637–642.
12.
XuYGuXGongMGuoGHanKAnR. Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment. Cancer Biol Ther2013; 14: 897–906.
13.
DancerJYTruongLDZhaiQShenSS. Expression of Galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker. Arch Pathol Lab Med2010; 134: 90–94.
14.
SakakiMFukumoriTFukawaTElsammanEShiirevnyambaANakatsujiHKanayamaHO. Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest2010; 57: 152–157.
15.
ZhuGWangXWuSLiQ. Involvement of activation of PI3K/Akt pathway in the protective effects of puerarin against MPP+-induced human neuroblastoma SH-SY5Y cell death. Neurochem Int2012; 60: 400–408.
16.
YoshiiTInoharaHTakenakaYHonjoYAkahaniSNomuraTRazAKuboT. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol2001; 18: 787–792.
HsuDKHammesSRKuwabaraIGreeneWCLiuFT. Human T lymphotropic virus-I infection of human T lymphocytes induces expression of the beta-galactoside-binding lectin, galectin-3. Am J Pathol1996; 148: 1661–1670.
19.
LiYXuXWangLLiuGLiYWuXJingYLiHWangG. Senescent mesenchymal stem cells promote colorectal cancer cells growth via galectin-3 expression. Cell Biosci2015; 5: 21–21.
20.
ElolaMTBlidnerAGFerragutFBracalenteCRabinovichGA. Assembly, organization and regulation of cell-surface receptors by lectin-glycan complexes. Biochem J2015; 469: 1–16.
21.
ArnoysEJAckermanCMWangJL. Nucleocytoplasmic shuttling of galectin-3. Methods Mol Biol2015; 1207: 465–483.
22.
ShanJZhaoWGuW. Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol Cell2009; 36: 469–476.
23.
LinHMPestellRGRazAKimHR. Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene2002; 21: 8001–8010.
24.
KirlaRMHaapasaloHKKalimoHSalminenEK. Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer2003; 97: 644–648.
25.
MollerMB. P27 in cell cycle control and cancer. Leuk Lymphoma2000; 39: 19–27.
26.
O'DriscollLLinehanRLiangYHJoyceHOglesbyIClynesM. Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro. Anticancer Res2002; 22: 3117–3125.
27.
BresalierRSMazurekNSternbergLRByrdJCYunkerCKNangia-MakkerPRazA. Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. Gastroenterology1998; 115: 287–296.
28.
NishiyamaJKobayashiSIshidaANakabayashiITajimaOMiuraSKatayamaMNogamiH. Up-regulation of galectin-3 in acute renal failure of the rat. Am J Pathol2000; 157: 815–823.
29.
DelacourDCramm-BehrensCIDrobecqHLe BivicANaimHYJacobR. Requirement for galectin-3 in apical protein sorting. Curr Biol2006; 16: 408–414.
30.
ZhaoQDuckworthCAWangWGuoXBarrowHPritchardDMRhodesJMYuLG. Peanut agglutinin appearance in the blood circulation after peanut ingestion mimics the action of endogenous galectin-3 to promote metastasis by interaction with cancer-associated MUC1. Carcinogenesis2014; 35: 2815–2821.
31.
ParkGBKimDJKimYSLeeHKKimCWHurDY. Silencing of galectin-3 represses osteosarcoma cell migration and invasion through inhibition of FAK/Src/Lyn activation and beta-catenin expression and increases susceptibility to chemotherapeutic agents. Int J Oncol2015; 46: 185–194.
32.
SerizawaNTianJFukadaHBaghyKScottFChenXKissZOlsonKHsuDLiuFTTörökNJZhaoBJiangJX. Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation. Lab Invest2015; 95: 1145–1156.
33.
NakaharaSOkaNRazA. On the role of galectin-3 in cancer apoptosis. Apoptosis2005; 10: 267–275.
34.
HarazonoYKhoDHBalanVNakajimaKZhangTHoganVRazA. Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells. Oncotarget2014; 5: 9992–10001.
